Aficamten Outperforms Beta-Blockers in Treating Patients with Obstructive Hypertrophic Cardiomyopathy

Aficamten outperforms beta-blockers in treating patients with obstructive hypertrophic cardiomyopathy

Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

ESC 2025: Cytokinetics’ oHCM drug outperforms SoC beta blockers

Cytokinetics’ aficamten outperformed metoprolol in the Phase III MAPLE-HCM trial in patients with obstructive hypertrophic cardiomyopathy (oHCM).The post ESC 2025: Cytokinetics’ oHCM drug outperforms SoC beta blockers appeared first on Clinical Trials Arena.